---
document_datetime: 2025-12-29 11:29:24
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/briumvi.html
document_name: briumvi.html
version: success
processing_time: 0.1113373
conversion_datetime: 2025-12-30 02:37:17.633773
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Briumvi

[RSS](/en/individual-human-medicine.xml/67673)

##### Authorised

This medicine is authorised for use in the European Union

ublituximab Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Briumvi](#news-on)
- [More information on Briumvi](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Briumvi is a medicine for treating adults with relapsing forms of multiple sclerosis (a disease of the brain and spinal cord in which inflammation destroys the protective covering around nerves and damages the nerves), where the patient has flare-ups (relapses) followed by periods with milder or no symptoms. It is used in patients with active disease, which means that they have relapses and/or signs of active inflammation on scans.

Briumvi contains the active substance ublituximab.

Expand section

Collapse section

## How is Briumvi used?

The medicine can only be obtained with a prescription and treatment should be started by a doctor experienced in the diagnosis and treatment of conditions of the nervous system and who has access to appropriate medical support to manage severe reactions such as serious infusion related reactions.

Briumvi is available as a solution for infusion. Treatment starts with one infusion (drip) into a vein followed by another infusion 2 weeks later. After the first two doses, infusions are given every 24 weeks.

To reduce the risk of infusion-related reactions, patients will receive other medicines before treatment.

For more information about using Briumvi, see the package leaflet or contact your healthcare provider.

## How does Briumvi work?

The active substance in Briumvi, ublituximab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a specific target called CD20 on the surface of B cells (a type of white blood cell).

B cells play a key role in multiple sclerosis by attacking the protective covering (sheaths) around the nerves in the brain and spinal cord and the nerves themselves, causing inflammation and damage. By targeting B cells, ublituximab helps to reduce their activity and helps to prevent flare-ups.

## What benefits of Briumvi have been shown in studies?

Studies have shown that Briumvi is effective at reducing the number of relapses.

In two main studies of 1,089 patients with relapsing forms of multiple sclerosis, the average number of yearly relapses in patients treated with Briumvi was less than half that in patients treated with another multiple sclerosis medicine, teriflunomide (0.09 versus 0.23 relapses per year). The studies also showed that patients treated with Briumvi had fewer lesions in scans of the brain than patients taking teriflunomide (0.013 versus 0.38 lesions per scan) indicating less active multiple sclerosis.

## What are the risks associated with Briumvi?

For the full list of side effects and restrictions with Briumvi, see the package leaflet.

The most common side effects with Briumvi (which may affect more than 1 in 10 people) include infusion-related reactions and infections.

## Why is Briumvi authorised in the EU?

Studies showed that Briumvi is effective at reducing the number of relapses in patients with relapsing forms of multiple sclerosis. While Briumvi did not show a significant impact in terms of preventing disability due to MS from getting worse, this could be attributed to the low number of patients whose disease progressed in the study. Side effects are in line with those of other similar medicines and are considered manageable. The European Medicines Agency decided that Briumvi's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Briumvi?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Briumvi have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Briumvi are continuously monitored. Suspected side effects reported with Briumvi are carefully evaluated and any necessary action taken to protect patients.

## Other information about Briumvi

Briumvi received a marketing authorisation valid throughout the EU on 31 May 2023.

Briumvi : EPAR - Medicine overview

Reference Number: EMA/281688/2023

English (EN) (138.11 KB - PDF)

**First published:** 13/07/2023

[View](/en/documents/overview/briumvi-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-913)

български (BG) (143.46 KB - PDF)

**First published:**

13/07/2023

[View](/bg/documents/overview/briumvi-epar-medicine-overview_bg.pdf)

español (ES) (118.79 KB - PDF)

**First published:**

13/07/2023

[View](/es/documents/overview/briumvi-epar-medicine-overview_es.pdf)

čeština (CS) (140.41 KB - PDF)

**First published:**

13/07/2023

[View](/cs/documents/overview/briumvi-epar-medicine-overview_cs.pdf)

dansk (DA) (118.42 KB - PDF)

**First published:**

13/07/2023

[View](/da/documents/overview/briumvi-epar-medicine-overview_da.pdf)

Deutsch (DE) (121.98 KB - PDF)

**First published:**

13/07/2023

[View](/de/documents/overview/briumvi-epar-medicine-overview_de.pdf)

eesti keel (ET) (117.46 KB - PDF)

**First published:**

13/07/2023

[View](/et/documents/overview/briumvi-epar-medicine-overview_et.pdf)

ελληνικά (EL) (140.45 KB - PDF)

**First published:**

13/07/2023

[View](/el/documents/overview/briumvi-epar-medicine-overview_el.pdf)

français (FR) (119.61 KB - PDF)

**First published:**

13/07/2023

[View](/fr/documents/overview/briumvi-epar-medicine-overview_fr.pdf)

hrvatski (HR) (139.33 KB - PDF)

**First published:**

13/07/2023

[View](/hr/documents/overview/briumvi-epar-medicine-overview_hr.pdf)

italiano (IT) (117.67 KB - PDF)

**First published:**

13/07/2023

[View](/it/documents/overview/briumvi-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (148.22 KB - PDF)

**First published:**

13/07/2023

[View](/lv/documents/overview/briumvi-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (140.72 KB - PDF)

**First published:**

13/07/2023

[View](/lt/documents/overview/briumvi-epar-medicine-overview_lt.pdf)

magyar (HU) (140.25 KB - PDF)

**First published:**

13/07/2023

[View](/hu/documents/overview/briumvi-epar-medicine-overview_hu.pdf)

Malti (MT) (143.82 KB - PDF)

**First published:**

13/07/2023

[View](/mt/documents/overview/briumvi-epar-medicine-overview_mt.pdf)

Nederlands (NL) (118.88 KB - PDF)

**First published:**

13/07/2023

[View](/nl/documents/overview/briumvi-epar-medicine-overview_nl.pdf)

polski (PL) (142.82 KB - PDF)

**First published:**

13/07/2023

[View](/pl/documents/overview/briumvi-epar-medicine-overview_pl.pdf)

português (PT) (120.08 KB - PDF)

**First published:**

13/07/2023

[View](/pt/documents/overview/briumvi-epar-medicine-overview_pt.pdf)

română (RO) (138.53 KB - PDF)

**First published:**

13/07/2023

[View](/ro/documents/overview/briumvi-epar-medicine-overview_ro.pdf)

slovenčina (SK) (139.95 KB - PDF)

**First published:**

13/07/2023

[View](/sk/documents/overview/briumvi-epar-medicine-overview_sk.pdf)

slovenščina (SL) (137.09 KB - PDF)

**First published:**

13/07/2023

[View](/sl/documents/overview/briumvi-epar-medicine-overview_sl.pdf)

Suomi (FI) (117.36 KB - PDF)

**First published:**

13/07/2023

[View](/fi/documents/overview/briumvi-epar-medicine-overview_fi.pdf)

svenska (SV) (117.35 KB - PDF)

**First published:**

13/07/2023

[View](/sv/documents/overview/briumvi-epar-medicine-overview_sv.pdf)

Briumvi : EPAR - Risk management plan

English (EN) (688.99 KB - PDF)

**First published:** 13/07/2023

**Last updated:** 15/12/2023

[View](/en/documents/rmp/briumvi-epar-risk-management-plan_en.pdf)

## Product information

Briumvi : EPAR - Product information

English (EN) (494.51 KB - PDF)

**First published:** 13/07/2023

**Last updated:** 08/10/2025

[View](/en/documents/product-information/briumvi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-923)

български (BG) (567.08 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/bg/documents/product-information/briumvi-epar-product-information_bg.pdf)

español (ES) (487.47 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/es/documents/product-information/briumvi-epar-product-information_es.pdf)

čeština (CS) (547.25 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/cs/documents/product-information/briumvi-epar-product-information_cs.pdf)

dansk (DA) (492.06 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/da/documents/product-information/briumvi-epar-product-information_da.pdf)

Deutsch (DE) (509.28 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/de/documents/product-information/briumvi-epar-product-information_de.pdf)

eesti keel (ET) (485.94 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/et/documents/product-information/briumvi-epar-product-information_et.pdf)

ελληνικά (EL) (525.76 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/el/documents/product-information/briumvi-epar-product-information_el.pdf)

français (FR) (500.3 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/fr/documents/product-information/briumvi-epar-product-information_fr.pdf)

hrvatski (HR) (536.52 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/hr/documents/product-information/briumvi-epar-product-information_hr.pdf)

íslenska (IS) (487.09 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/is/documents/product-information/briumvi-epar-product-information_is.pdf)

italiano (IT) (490.63 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/it/documents/product-information/briumvi-epar-product-information_it.pdf)

latviešu valoda (LV) (526.43 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/lv/documents/product-information/briumvi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (525.99 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/lt/documents/product-information/briumvi-epar-product-information_lt.pdf)

magyar (HU) (563.21 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/hu/documents/product-information/briumvi-epar-product-information_hu.pdf)

Malti (MT) (573.42 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/mt/documents/product-information/briumvi-epar-product-information_mt.pdf)

Nederlands (NL) (503.19 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/nl/documents/product-information/briumvi-epar-product-information_nl.pdf)

norsk (NO) (492.09 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/no/documents/product-information/briumvi-epar-product-information_no.pdf)

polski (PL) (576.97 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/pl/documents/product-information/briumvi-epar-product-information_pl.pdf)

português (PT) (478.37 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/pt/documents/product-information/briumvi-epar-product-information_pt.pdf)

română (RO) (525.67 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/ro/documents/product-information/briumvi-epar-product-information_ro.pdf)

slovenčina (SK) (574.5 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/sk/documents/product-information/briumvi-epar-product-information_sk.pdf)

slovenščina (SL) (558.63 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/sl/documents/product-information/briumvi-epar-product-information_sl.pdf)

Suomi (FI) (489.96 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/fi/documents/product-information/briumvi-epar-product-information_fi.pdf)

svenska (SV) (486.94 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

08/10/2025

[View](/sv/documents/product-information/briumvi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000279394 04/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Briumvi : EPAR - All authorised presentations

English (EN) (103 KB - PDF)

**First published:** 13/07/2023

**Last updated:** 19/02/2024

[View](/en/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-335)

български (BG) (107.03 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/bg/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_bg.pdf)

español (ES) (104.21 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/es/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (104.36 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/cs/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (100.99 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/da/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (100.96 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/de/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (95.74 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/et/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (102.94 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/el/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_el.pdf)

français (FR) (102.63 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/fr/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (101.11 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/hr/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (100.47 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/is/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (97.79 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/it/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (103.53 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/lv/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (102.45 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/lt/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (101.63 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/hu/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (103.97 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/mt/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (103.91 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/nl/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (96.34 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/no/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_no.pdf)

polski (PL) (105.17 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/pl/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_pl.pdf)

português (PT) (99.93 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/pt/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_pt.pdf)

română (RO) (101.56 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/ro/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (104.46 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/sk/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (97.99 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/sl/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (96.53 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/fi/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (94.59 KB - PDF)

**First published:**

13/07/2023

**Last updated:**

19/02/2024

[View](/sv/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Briumvi Active substance ublituximab International non-proprietary name (INN) or common name ublituximab Therapeutic area (MeSH)

- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis

Anatomical therapeutic chemical (ATC) code L04

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

## Authorisation details

EMA product number EMEA/H/C/005914

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Neuraxpharm Pharmaceuticals S.L.

Avinguda De Barcelona 69 Poligono Industrialde La Fuensanta 08970 Sant Joan Despi SPAIN

Opinion adopted 30/05/2023 Marketing authorisation issued 31/05/2023 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Briumvi : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (151.72 KB - PDF)

**First published:** 08/10/2025

[View](/en/documents/procedural-steps-after/briumvi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Briumvi : EPAR - Procedural steps taken and scientific information after the authorisation (archive)

English (EN) (162.82 KB - PDF)

**First published:** 18/10/2023

**Last updated:** 08/10/2025

[View](/en/documents/procedural-steps-after/briumvi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Briumvi-H-C-PSUSA-00000045-202406 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/153744/2025

English (EN) (128.48 KB - PDF)

**First published:** 06/05/2025

[View](/en/documents/scientific-conclusion/briumvi-h-c-psusa-00000045-202406-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Briumvi : EPAR - Public assessment report

Adopted

Reference Number: EMA/173313/2023

English (EN) (8.17 MB - PDF)

**First published:** 13/07/2023

**Last updated:** 07/02/2024

[View](/en/documents/assessment-report/briumvi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Briumvi

Adopted

Reference Number: EMA/CHMP/122125/2023

English (EN) (143.02 KB - PDF)

**First published:** 31/03/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-briumvi_en.pdf)

#### News on Briumvi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27 - 30 March 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-march-2023) 31/03/2023

#### More information on Briumvi

- [EMEA-002889-PIP02-20-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002889-pip02-20-m01)
- [BRIUMVI® Pregnancy Registry: A Prospective Study of Pregnancy and Infant Outcomes in Patients Treated with BRIUMVI® - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000614)
- [A Long-Term Observational Study of the Safety of Ublituximab Patients with Relapsing Multiple Sclerosis in a Real-World Setting (ENLIGHTEN) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000611)
- [TG1101-RMS404 - A Post-Authorization Study to Characterize the Safety of BRIUMVI (ublituximab) Use in Pregnant Patients with Multiple Sclerosis Using Data from a US Administrative Healthcare Claims Database - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000612)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 08/10/2025

## Share this page

[Back to top](#main-content)